Skip to main content

Peer Review reports

From: The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR -mutated and -wildtype non-small cell lung cancer cells

Original Submission
11 Dec 2014 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
1 Dec 2015 Editorially accepted
16 Dec 2015 Article published 10.1186/s12885-015-1967-5

You can find further information about peer review here.

Back to article page